

processes, and procedures, that are accountable and transparent, beginning with the per diem methodology to aid in meeting agency missions in an effective and efficient manner at the lowest logical travel cost. Through the review process, the GTAC will address current industry and Federal travel trends and provide advice and make recommendations for improvements to increase travel efficiency and effectiveness, reduce costs, promote sustainability, and incorporate industry best practices. The Committee provides an opportunity for travel industry leaders, and other qualified individuals to offer their expert advice and recommendations to GSA, which among other things, is responsible for the development and implementation of the FTR which prescribes the policies for travel by Federal civilian employees and others authorized to travel at Government expense. These views will be offered to the Administrator of General Services on a regular basis. There exists no other source within the Federal government that could serve this function. The GTAC shall be a continuing advisory committee with an initial two-year term and will automatically expire two years from the date of the charter filing, unless renewed prior to expiration. The GTAC will be comprised of no more than 15 members, including the Chair, with extensive knowledge and expertise in travel management. The Chair will be selected from among the membership by GSA. Members may include Federal agency travel managers, hoteliers, rental car companies, airline companies, travel and lodging associations, convention and visitor bureaus, state and local government representatives, as well as corporations. GTAC members will serve a two-year term with the possibility of a one-year extension. Membership in the GTAC is limited to the individuals appointed and is non-transferrable. No person who is a Federally-registered lobbyist may serve on the GTAC. GTAC members will not receive compensation or travel reimbursements from the Government. The meetings are open to public observers, unless prior notice has been provided for a closed meeting.

Nomination for Advisory Committee Appointment: There is no prescribed format for the nomination. Individuals may nominate themselves or other individuals. A nomination package should include the following information for each nominee: (1) A letter of nomination stating the name, affiliation, and contact information for the nominee, membership capacity he/she will serve, nominee's field(s) of

expertise, description of their interest, and qualifications (2) a complete professional biography or resume of the nominee; and (3) the name, return address, email address, and daytime telephone number at which the nominator can be contacted. GSA will consider nominations of all qualified individuals to ensure that the GTAC includes the areas of travel subject matter expertise needed. Potential candidates may be asked to provide detailed information concerning financial interests that might be affected by recommendations of the GTAC to permit evaluation of possible sources of conflicts of interest. The nomination period for interested candidates will close 30 days after publication of this notice. All nominations should be submitted in sufficient time to be received by 5 p.m. Eastern Standard Time on the closing date and be addressed to email address mailto:gtac@gsa.gov or by mail to: General Services Administration, Office of Government-wide Policy, 1275 First Street NE., One Constitution.

Dated: December 17, 2012.

Chris Scott,

Director, Travel and Relocation Policy, Office of Asset and Transportation Management, Office of Government Policy.

[FR Doc. 2012-30928 Filed 12-21-12; 8:45 am]

BILLING CODE 6820-14-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

Terry S. Elton, Ph.D., The Ohio State University: Based on the reports of two investigations conducted by The Ohio State University (OSU) and additional analysis conducted by ORI in its oversight review, ORI found that Dr. Terry S. Elton, Professor, College of Pharmacy and Davis Heart and Lung Research Institute, OSU, engaged in research misconduct in research supported by National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), grants R01 HL048848, R01 HL084498, and P01 HL70294, National Institute of Child Health and Human Development (NICHD), NIH, grant R21 HD058997, National Institute on Aging (NIA), NIH,

grant R01 AG021912, National Institute of Allergy and Infectious Diseases (NIAID), NIH, grant R01 AI39963, and National Eye Institute (NEI), NIH, grant R01 ES012241.

ORI found that the Respondent engaged in research misconduct by falsifying and/or fabricating data that were included in 1 R21 HD058997-01, 1 R21 HD058997-01A1, 1 R21 HD058997-01A2, 1 RC1 HL100298-01, and in:

1. Kuhn, D.E., Nuovo, G.J., Terry, A.V. Jr., Martin, M.M., Malana, G.E., Sansom, S.E., Pleister, A.P., Beck, W.D., Head, E., Feldman, D.S., & Elton, T.S. "Chromosome 21-derived microRNAs provide an etiological basis for aberrant protein expression in human Down syndrome brains." *J Biol Chem* 285(2):1529-43, 2010 Jan 8.
2. Kuhn, D.E., Nuovo, G.J., Martin, M.M., Malana, G.E., Pleister, A.P., Jiang, J., Schmittgen, T.D., Terry, A.V. Jr., Gardiner, K., Head, E., Feldman, D.S., & Elton, T.S. "Human chromosome 21-derived miRNAs are overexpressed in Down syndrome brains and hearts." *Biochem Biophys Res Commun* 370(3):473-7, 2008 Jun 6.
3. Martin, M.M., Buckenberger, J.A., Jiang, J., Malana, G.E., Knoell, D.L., Feldman, D.S., & Elton, T.S. "TGFβ1 stimulates human AT1 receptor expression in lung fibroblasts by cross talk between the Smad, p38 MAPK, JNK, and PI3K signaling pathways." *Am. J. Physiol. Lung Cell. Mol. Physiol.* 293(3):L790-9, 2007 Sept. (Retracted: *Am. J. Physiol. Lung Cell. Mol. Physiol.* 302(7):L719, 2012 Apr.)
4. Martin, M.M., Buckenberger, J.A., Jiang, J., Malana, G.E., Nuovo, G.J., Chotani, M., Feldman, D.S., Schmittgen, T.D., & Elton, T.S. "The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microRNA-155 binding." *J Biol Chem* 282(33):24262-9, 2007, Aug 17.
5. Martin, M.M., Buckenberger, J.A., Knoell, D.L., Strauch, A.R., & Elton, T.S. "TGF-beta(1) regulation of human AT1 receptor mRNA splice variants harboring exon 2." *Mol Cell Endocrinol* 249(1-2):21-31, 2006 Apr 25.
6. Duffy, A.A., Martin, M.M., & Elton, T.S. "Transcriptional regulation of the AT1 receptor gene in immortalized human trophoblast cells." *Biochim. Biophys. Acta.* 1680(3):158-70, 2004 Nov 5.

As a result of its investigation, OSU has recommended that all of the above publications be retracted.

Specifically, ORI finds that Respondent:

- Falsified and/or fabricated Western blots in an NIH grant application in three submissions of the same grant application:

- Figures 4, 7, 11C: 1 R21 HD058997–01

- Figures 7B, 7E, 8B: 1 R21 HD058997–01A1

- Figures 3C, 3F, 6C: 1 R21 HD058997–01A2

and false Western blots were also included in Figure 6 in grant application 1 RC1 HL100298–01.

- Falsified and/or fabricated Western blots in eighteen (18) figures and in six (6) published papers. Specifically false and/or fabricated images were included in:

- Figures 2C, 2D, 2F, 3C, 3E, 4G, 5C, 5F: *J Biol Chem* 285(2):1529–43, 2010 Jan 8

- Figures 3B, 3C, 3F, 3H, 3I, 3J: *Biochem Biophys Res Commun* 370(3):473–7, 2008 Jun 6

- Figures 2, 3, 4B, 5B, 6, 7B, 8A, 9B: *Am. J. Physiol. Lung Cell. Mol. Physiol.* 293(3):L790–9, 2007 Sept

- Figure 6: *J Biol Chem* 282(33):24262–9, 2007 Aug 17

- Figure 6: *Mol Cell Endocrinol* 249(1–2):21–31, 2006 Apr 25

- Figures 5, 6B, 7B, 9B: *Biochim. Biophys. Acta* 1680(3):158–70, 2004 Nov 5.

Dr. Elton has entered into a Voluntary Exclusion Agreement and has voluntarily agreed:

(1) To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as “covered transactions” pursuant to HHS’ Implementation (2 CFR part 376 *et seq.*) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the “Debarment Regulations”) for a period of three (3) years, beginning on November 26, 2012;

(2) To exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of three (3) years, beginning on November 26, 2012; and

(3) To request that the following publications be retracted:

- *J Biol Chem* 285(2):1529–43, 2010 Jan 8

- *Biochem Biophys Res Commun* 370(3):473–7, 2008 Jun 6

- *J Biol Chem* 282(33):24262–9, 2007, Aug 17

- *Mol Cell Endocrinol* 249(1–2):21–31, 2006 Apr 25

- *Biochim. Biophys. Acta*.

1680(3):158–70, 2004 Nov 5.

FOR FURTHER INFORMATION CONTACT:

Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8200.

John E. Dahlberg,

Deputy Director, Office of Research Integrity.

[FR Doc. 2012–30866 Filed 12–21–12; 8:45 am]

BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Meeting of the Presidential Commission for the Study of Bioethical Issues

AGENCY: Department of Health and Human Services, Office of the Assistant Secretary for Health, Presidential Commission for the Study of Bioethical Issues.

ACTION: Notice of meeting.

SUMMARY: The Presidential Commission for the Study of Bioethical Issues (the Commission) will conduct its twelfth meeting in January. At this meeting, the Commission will continue discussing topics related to the ethical issues associated with the development of medical countermeasures for children.

DATES: The meeting will take place Monday and Tuesday, January 14–15, 2013.

ADDRESSES: University of Miami Hospital Seminar Center, 1400 NW. 12th Avenue, First Floor, Miami, Florida 33136. Telephone (305) 689–5511.

FOR FURTHER INFORMATION CONTACT:

Hillary Wicai Viers, Communications Director, Presidential Commission for the Study of Bioethical Issues, 1425 New York Avenue NW., Suite C–100, Washington, DC 20005. Telephone: 202–233–3960. Email: Hillary.Viers@bioethics.gov. Additional information may be obtained at www.bioethics.gov.

SUPPLEMENTARY INFORMATION: Pursuant to the Federal Advisory Committee Act of 1972, Public Law 92–463, 5 U.S.C. app. 2, notice is hereby given of the twelfth meeting of the Commission. The meeting will be held from 9 a.m. to approximately 5 p.m. on Monday, January 14, 2013, and from 9 a.m. to approximately 11:45 a.m. on Tuesday,

January 15, 2013, in Miami, Fla. The meeting will be open to the public with attendance limited to space available. The meeting will also be webcast at www.bioethics.gov.

Under authority of Executive Order 13521, dated November 24, 2009, the President established the Commission. The Commission is an advisory panel of the nation’s leaders in medicine, science, ethics, religion, law, and engineering. The Commission advises the President on bioethical issues arising from advances in biomedicine and related areas of science and technology. The Commission seeks to identify and promote policies and practices that ensure scientific research, health care delivery, and technological innovation are conducted in a socially and ethically responsible manner.

The main agenda item for the Commission’s twelfth meeting is to continue discussing topics related to the ethical issues associated with the development of medical countermeasures for children.

The draft meeting agenda and other information about the Commission, including information about access to the webcast, will be available at www.bioethics.gov.

The Commission welcomes input from anyone wishing to provide public comment on any issue before it. Respectful debate of opposing views and active participation by citizens in public exchange of ideas enhances overall public understanding of the issues at hand and conclusions reached by the Commission. The Commission is particularly interested in receiving comments and questions during the meeting that are responsive to specific sessions. Written comments will be accepted at the registration desk and comment forms will be provided to members of the public in order to write down questions and comments for the Commission as they arise. To accommodate as many individuals as possible, the time for each question or comment may be limited. If the number of individuals wishing to pose a question or make a comment is greater than can reasonably be accommodated during the scheduled meeting, the Commission may make a random selection.

Anyone planning to attend the meeting who needs special assistance, such as sign language interpretation or other reasonable accommodations, should notify Esther Yoo by telephone at (202) 233–3960, or email at Esther.Yoo@bioethics.gov in advance of the meeting. The Commission will make every effort to accommodate persons who need special assistance.